Get the Stockscreener App
5.855
7.14%
0.395
Annexon Inc stock is traded at $5.855, with a volume of 2.63M.
It is up +7.14% in the last 24 hours and up +10.59% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.46
Open:
$5.43
24h Volume:
2.63M
Relative Volume:
0.89
Market Cap:
$959.30M
Revenue:
-
Net Income/Loss:
$-196.48M
P/E Ratio:
-4.8158
EPS:
-1.2158
Net Cash Flow:
$-183.16M
1W Performance:
+5.03%
1M Performance:
+10.59%
6M Performance:
+14.71%
1Y Performance:
+102.42%
1-Day Range:
$5.39
$6.00
1-Week Range:
$5.275
$6.04
52-Week Range:
$1.85
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.855 | 935.54M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon, Inc.(NasdaqGS: ANNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2500 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2000 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 3000E Growth Benchmark - marketscreener.com
ANNX Forecast — Price Target — Prediction for 2027 - TradingView
Annexon, Inc. Actuals & Estimates (NASDAQ:ANNX) - TradingView
Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook - 富途牛牛
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annexon (ANNX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Annexon (ANNX) AGM 2026 Summary - Quartr
Annexon unveils six Guillain-Barre syndrome studies at PNS2026 global forum - Traders Union
ANNX Stock Price, Quote & Chart - ChartMill
ANNX News | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Inc (ANNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annexon Inc (ANNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annexon Inc (ANNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annexon Inc (ANNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annexon Inc (ANNX) Institutional Confidence - TradingKey
Annexon Inc (ANNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Two new Annexon hires receive options on 705,000 shares - Stock Titan
Annexon (ANNX) director William Waddill receives 65,000 stock options grant - Stock Titan
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant - Stock Titan
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70 - Stock Titan
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares - Stock Titan
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEarnings Sentiment Score - newsline.com
Annexon Stockholders Approve Directors, Compensation and Share Increase - The Globe and Mail
Annexon Inc. (ANNX) Holds Steady Near Support as Biotech Sector Faces HeadwindsRisk Parity Rebalance - newsline.com
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes - Stock Titan
Annexon Inc. (ANNX) Gains 2.13% as Biotech Stock Holds Above Key SupportCounter Trend Trade - newsline.com
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027 - TradingView
Annexon Inc Annual Shareholders Meeting Transcript - GuruFocus
Annexon eyes 'win season' with Q4 vision trial data, GBS filings ahead - MSN
Annexon maps 3 big pipeline catalysts ahead of Q4 vision-drug readout - MSN
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead - MarketBeat
Annexon Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - sharewise.com
ANNX: Three major clinical data readouts expected in 2024, each with strong differentiation - TradingView
Annexon Inc. (ANNX) Holds Steady Near Support as Consolidation ContinuesBeta Neutral Pair - newsline.com
ANNX Q1 2026 Earnings: EPS Beat Guidance as Clinical Progress ContinuesSubscription Growth Report - The Legal Advocate
Annexon(ANNX.US) Director Buys US$3.32 Million in Common Stock - Moomoo
Annexon Inc. (ANNX) Shows Modest Gain: Biotech Stock Tests Key LevelsWide Range Bar - The Legal Advocate
Insider Purchase: Director at $ANNX Buys 613,497 Shares - Moomoo
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Satter Muneer A | Director |
May 28 '26 |
Buy |
5.41 |
613,497 |
3,319,019 |
10,342,134 |
| Carson William H. | Director |
May 11 '26 |
Buy |
5.78 |
8,000 |
46,240 |
78,405 |
| Carson William H. | Director |
Apr 10 '26 |
Buy |
6.20 |
8,000 |
49,600 |
70,405 |
| Carson William H. | Director |
Mar 10 '26 |
Buy |
5.67 |
8,000 |
45,360 |
62,405 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,820 |
31,603 |
123,582 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Mar 02 '26 |
Sale |
5.42 |
4,339 |
23,517 |
182,625 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,566 |
30,168 |
154,161 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,894 |
32,004 |
180,093 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,565 |
30,162 |
170,700 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):